An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Therapeutics

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2010.07.013PMID 20678684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole

  2010cited by this paper
• In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers

  2009cited by this paper
• Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use

  2009cited by this paper
• Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054

  2009cited by this paper
• Midazolam and other benzodiazepines.

  2008cited by this paper
• Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis

  2007cited by this paper
• Comparison of midazolam and simvastatin as cytochrome P450 3A probes

  2006cited by this paper
• Mechanisms leading to the development of hormone-resistant prostate cancer.

  2006cited by this paper
• ZD4054, a Potent Endothelin Receptor A Antagonist, Inhibits Ovarian Carcinoma Cell Proliferation

  2006cited by this paper
• Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma

  2005cited by this paper
• Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence

  2005cited by this paper
• Endothelin-1 inhibits apoptosis in prostate cancer.

  2005cited by this paper
• Therapeutic options in androgen‐independent prostate cancer: building on docetaxel

  2005cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Prostate Cancer Incidence and Mortality Rates and Trends in the United States and Canada

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Targeting endothelin axis in cancer.

  2004cited by this paper
• Role of endothelin‐1 in osteoblastic bone metastases

  2003cited by this paper
• Emerging role of endothelin-1 in tumor angiogenesis.

  2003cited by this paper
• The endothelin axis: emerging role in cancer

  2003cited by this paper
• Ethical principles for medical research involving human subjects

  2003cited by this paper
• Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.

  2001cited by this paper
• Expression of endothelin receptor a associated with prostate cancer progression.

  2001cited by this paper
• Cytochrome P-450 3A4: regulation and role in drug metabolism.

  1999cited by this paper
• Endothelin-induced Apoptosis of A375 Human Melanoma Cells*

  1998cited by this paper
• Midazolam: a review of therapeutic uses and toxicity.

  1997cited by this paper
• Cross-over trials in clinical research

  1993cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Cytochrome P-450: Structure, Mechanism, and Biochemistry

  1986cited by this paper

• Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study

  2024influential citation
• π–π Noncovalent Interaction Involving 1,2,4- and 1,3,4-Oxadiazole Systems: The Combined Experimental, Theoretical, and Database Study

  2021cites this paper
• A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

  2013cites this paper
• Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors

  2012cites this paper
• Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers

  2012cites this paper